- Disease:Metabolic dysfunction-associated liver disease
- Substances:Ly3437943 SodiumTirzepatide
Countries:
Norway
Norway- Participants:18–64 years · 65+ years
- Substances:Ly3437943 Sodium
- Sponsor:Eli Lilly & Co.
Back to NorwayClinical trials in Tromsø – page 2
141 clinical trials in Tromsø, Norway across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in NorwayKliniske-Studier.no(opens in a new tab)Tromsø at a glance
141
clinical trials
- Research sites1
Recruiting
Acute myeloid leukaemia
RecruitingInvestigational
A study of bleximenib combined with intensive chemotherapy for adults with newly diagnosed acute myeloid leukemia with specific genetic changes.
Investigational
- Disease:Acute myeloid leukaemia
- Substances:BLEXIMENIB
Countries:Norway
Norway- Participants:18–64 years · 65+ years
- Substances:BLEXIMENIB
- Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
Recruiting
B-cell type acute leukaemia
RecruitingRegistered drugNo placebo
Study of chemotherapy with blinatumomab and tyrosine kinase inhibitors in newly diagnosed children and young adults with Philadelphia chromosome positive B-cell acute lymphoblastic leukemia
Registered drugNo placebo
- Disease:B-cell type acute leukaemia
- Substances:Blinatumomab
Countries:Norway
Norway- Participants:0–17 years · 18–64 years
- Substances:Blinatumomab
- Sponsor:Universita Degli Studi Di Milano Bicocca
Recruiting
Registered drugNo placebo
A study of drug combination (clopidogrel, acetylsalicylic acid, atorvastatin, rosuvastatin) for patients with covert brain infarction
Registered drugNo placebo
- Substances:Acetylsalicylic AcidAtorvastatin+2
Countries:Norway
Norway- Participants:18–64 years · 65+ years
- Substances:Acetylsalicylic Acid
- Sponsor:Region Midtjylland
Recruiting
Metastatic gastric cancer
RecruitingRegistered drugNo placebo
Study of intraperitoneal paclitaxel combined with systemic therapy versus systemic therapy alone for patients with gastric cancer and peritoneal metastases
Registered drugNo placebo
- Disease:Metastatic gastric cancer
- Substances:CapecitabineDocetaxel+8
Countries:Norway
Norway- Participants:18–64 years · 65+ years
- Substances:Capecitabine
- Sponsor:Karolinska University Hospital
Recruiting
Sepsis
RecruitingRegistered drugNo placebo
Comparison of Gentamicin with Narrow-Spectrum Antibiotics versus Broad-Spectrum Antibiotics in Adult Patients with Early Sepsis
Registered drugNo placebo
- Disease:Sepsis
- Substances:Ampicillin SodiumCefotaxime+9
Countries:Norway
Norway- Participants:18–64 years · 65+ years
- Substances:Ampicillin Sodium
- Sponsor:Akershus University Hospital
Recruiting
Endometrial cancer
RecruitingRegistered drugNo placebo
Study of Sacituzumab Tirumotecan and Pembrolizumab for Patients with Advanced or Recurrent Endometrial Cancer
Registered drugNo placebo
- Disease:Endometrial cancer
- Substances:CarboplatinCodeine Phosphate+7
Countries:Norway
Norway- Participants:18–64 years · 65+ years
- Substances:Carboplatin
- Sponsor:Merck Sharp & Dohme LLC
Recruiting
Cough
RecruitingRegistered drug
Study on the Effectiveness of Amoxicillin and Clavulanic Acid in Treating Chronic Wet Cough in Young Children
Registered drug
- Disease:Cough
- Substances:AmoxicillinClavulanic Acid
Countries:Norway
Norway- Participants:0–17 years · Healthy volunteers
- Substances:Amoxicillin
- Sponsor:Helse Stavanger HF
Recruiting
Interstitial lung disease
RecruitingRegistered drug
Study of Rituximab versus Placebo to Improve Lung Function in Patients with Granulomatous Lymphocytic Interstitial Lung Disease (GLILD)
Registered drug
- Disease:Interstitial lung disease
- Substances:RituximabSodium Chloride
Countries:Norway
Norway- Participants:18–64 years · 65+ years
- Substances:Rituximab
- Sponsor:Oslo University Hospital HF
Recruiting
Ovarian cancer
RecruitingRegistered drugNo placebo
Study Comparing Rinatabart Sesutecan with Other Treatments for Patients with Platinum-Resistant Ovarian Cancer
Registered drugNo placebo
- Disease:Ovarian cancer
- Substances:Glatiramer AcetatePaclitaxel+4
Countries:Norway
Norway- Participants:18–64 years · 65+ years
- Substances:Glatiramer Acetate
- Sponsor:Genmab A/S
Recruiting
Migraine
RecruitingRegistered drug
Study on Reducing Chronic Migraine Days with CGRP Antibodies and Botulinum Toxin A in Adults Aged 18-70
Registered drug
- Disease:Migraine
- Substances:ErenumabFremanezumab+3
Countries:Norway
Norway- Participants:18–64 years · 65+ years
- Substances:Erenumab
- Sponsor:Oslo University Hospital HF
Recruiting
Amyotrophic lateral sclerosis
RecruitingRegistered drug
Study on the Effects of ILB and Riluzole for Patients with Amyotrophic Lateral Sclerosis (ALS)
Registered drug
- Disease:Amyotrophic lateral sclerosis
- Substances:Riluzole
Countries:Norway
Norway- Participants:18–64 years · 65+ years
- Substances:Riluzole
- Sponsor:Oslo University Hospital HF
Other cities in Norway
The busiest research cities in the country
Clinical research in Tromsø
What the registry says about research in the country
01 Oncology Studies
Multiple clinical trials focusing on innovative cancer treatments, including research on rare cancers, hepatoblastoma, and testicular cancer. Studies explore personalized treatment approaches and drug efficacy evaluation.
- Breast Cancer Biomarkers
- Pediatric Liver Tumors
- Advanced Endometrial Cancer
Novel therapeutic strategies and targeted treatments are being investigated to improve patient outcomes.
02 Neurological Disorders
Research focusing on Alzheimer's disease treatment and acute ischemic stroke management. Studies evaluate new drug comparisons and therapeutic interventions.
- Early Alzheimer's Treatment
- Stroke Thrombolysis
- Cognitive Function
Emphasis on developing effective therapeutic approaches for neurodegenerative conditions.
03 Pediatric Medicine
Comprehensive studies addressing various childhood conditions, including acute wheezing, leukemia, and respiratory infections.
- Childhood Respiratory Infections
- Pediatric Cancer Treatment
- Inflammatory Conditions
Focus on improving treatment outcomes in young patients through innovative therapeutic approaches.